Company intelligence / Profile preview

Intrance Medical Systems

New York, New York, United Statesintrancemedical.com ↗

Ownership: Private
Development stage: Other

Overview

Intrance Medical Systems is developing a fixed-dose combination treatment of levodopa, carbidopa, and entacapone for enteral infusion in advanced Parkinson's disease patients. The product is already marketed as Lecigon® in Europe. The company has received FDA clearance for its IND application and is advancing its clinical development program in the US.

Therapeutic areas: Neurology
Modalities: Fixed-dose combination drug delivered via enteral infusion
Industry: Biotech

Drug pipeline

1 asset

carbidopa + entacapone + levodopa

Commercial

Indications: Advanced Parkinson's disease

Partnerships

STADA/Britannia Pharmaceuticals (commercializing Lecigon® in Europe)

Beyond the preview

Go deeper on Intrance Medical Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intrance Medical Systems.